Search
phentermine/topiramate (Qnexa, Qsymia)
Indications:
- weight reduction (Qsymia refused FDA approval Oct 2010; renamed Qsymia & granted FDA approval July 2012)
- BMI >= 30 or >= 27 with comorbid condition (diabetes, hypertension)
Contraindications:
- glaucoma [5]
- nephrolithiasis
- hypertension
- pregnancy or lactation
* also see phentermine
Adverse effects:
- most common
- altered taste sensation
- constipation
- dizziness
- dry mouth
- insomnia
- paresthesia
- potential for causing birth defects & heart problems
* also see contraindications
Notes:
- average weight reduction of 20 pounds in one year [4]
General
pharmacologic combination
References
- Physician's First Watch for October 29, 2010
Massachusetts Medical Society
FirstWatch@jwatch.org
- Pollack A
F.D.A. Rejects Qnexa, a Third Weight-Loss Drug
NewYork Times, Oct 28. 2010
- Prescriber's Letter 19(4): 2012
Drugs for Weight Loss
Detail-Document#: 280403
(subscription needed) http://www.prescribersletter.com
- FDA News Release: July 17, 2012
FDA approves weight-management drug Qsymia
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm
- Prescriber's Letter 19(11): 2012
Drugs for Weight Loss
Detail-Document#: 281109
(subscription needed) http://www.prescribersletter.com
- Medical Knowledge Self Assessment Program (MKSAP) 17, 19
American College of Physicians, Philadelphia 2015. 2022
Components
phentermine (Fastin, Ionamin, Adipex)
topiramate (Topamax, Qudexy XR, Trokendi XR)